AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

ELUT · NASDAQ · Biotechnology

Elutia

Develops drug-eluting biomatrices for surgical reconstruction and implanted-device complications.

$0.8800

After-hours close−0.00 (−0.18%)

At close$0.8816(+0.18%)

Something off on this page? Send us feedback.

Profile

Elutia Inc.ELUTHealth Care

Develops drug-eluting biological matrices and sells the SimpliDerm franchise for surgical reconstruction. After selling legacy Orthobiologics and CIED businesses, it is focused on the NXT-41 and NXT-41x pipeline, whose advancement depends on FDA authorization.

Develops drug-eluting biologics, combining local drug delivery with biological materials for surgical applications. The remaining commercial franchise is SimpliDerm, while NXT-41 and NXT-41x are being advanced for complications associated with implanted devices.

After rebranding from Aziyo Biologics and selling the Orthobiologics and CIED businesses, operations narrowed around this platform. The Gaithersburg, Maryland site supports development and is intended for commercial production if FDA authorizations are obtained.

Production, laboratory, and administrative activities are concentrated at the Gaithersburg site. Advancement of NXT-41 and NXT-41x and future commercial production depend on FDA authorization.

Company facts

CEOC. Randal (Randy) Mills, Ph.D.

ListedOct 7, 2020

ExchangeNASDAQ

HeadquartersGaithersburg, MD

CountryUnited States

Employees26

CIK0001708527

ISINUS05479K1060

Key statistics

Market cap$38.9M

EPS (ttm)$0.9400

P/E (ttm)0.9362

ROE940.8%

P/B2.44

P/S3.21

Dividend yield—

Beta0.29vs XLV −0.10

Year to date +37.7% · Average volume (30d) 58.5K

Analysts

Price target, next 12 months$10.00+1,036.4%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy5 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.8800

High$10.50+1,093.2%

Median$10.00+1,036.4%

Low$5.00+468.2%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.15

ReportedDue Nov 12, 2026

Revenue

Estimate$1.0M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 13, 2026Q2 FY26	−$0.15	−$0.17	−13.3%	$2.9M	$2.4M	−16.3%	+9.38%
May 14, 2026Q1 FY26	−$0.15	−$0.17	−13.3%	$3.0M	$3.1M	+3.8%	−0.96%
Mar 11, 2026Q4 FY25	−$0.14	−$0.14	0.0%	$3.3M	$3.3M	−0.9%	+5.50%
Nov 6, 2025Q3 FY25	−$0.16	−$0.01	+93.5%	$3.3M	$3.3M	+0.7%	−5.00%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$6.0M	$6.3M	$3.3M	$3.3M	$3.1M	$2.4M
Gross profit	$2.5M	$3.1M	$1.9M	$1.9M	$1.8M	$1.4M
Operating income	−$7.9M	−$9.9M	−$4.4M	−$5.5M	−$5.7M	−$8.0M
Net income	−$3.9M	−$9.6M	−$3.9M	$70.8M	−$7.5M	−$7.6M
Diluted EPS	−$0.21	−$0.26	−$0.19	$1.48	−$0.17	−$0.18
Gross margin	40.7%	48.8%	55.8%	58.5%	57.9%	59.6%
Operating margin	-131.4%	-157.7%	-131.1%	-167.9%	-184.4%	-327.9%

Fiscal years (4-quarter sums)FY22 $42.6M · FY23 $24.7M · FY24 $24.4M · FY25 $18.9M

Revenue by product · Q2 FY26

Women'S Health$1.3M · 53%

Cardiovascular$1.1M · 47%

Balance sheet, Jun 30, 2026Cash & short-term investments $19.9M · Total debt $10.8M · Total assets $43.6M · Shareholders' equity $15.7M

Dividends

No dividends on record.

Ownership

Institutions —Insiders 25.20%

Shares outstanding 44.21M · Float —

Float — provider float is below the insider stake.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
HighCape Capital, L.P. · director, 10 percent owner:	9.52M	21.53%	Form 4	Mar 13, 2025
Nantahala Capital Management, LLC	4.12M	9.99%	13G	Feb 13, 2026
Orin Hirschman	3.07M	7.60%	13G	Jan 28, 2026
Knollwood Investment Advisory, LLC	2.56M	6.30%	13G	Feb 13, 2026
SilverArc Capital Management, LLC	1.78M	5.90%	13G	Feb 12, 2025

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jan 30, 2026	Guido J. Neels	director	+20,000	$1.04
Jan 30, 2026	Kevin Rakin	director, 10 percent owner:	+70,000	$1.06
Jan 28, 2026	Guido J. Neels	director	+15,000	$1.06
Jan 29, 2026	Guido J. Neels	director	+15,000	$1.06
Dec 17, 2025	Kevin Rakin	director, 10 percent owner:	+50,000	$0.5199